Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 10:32:30 26/06/2024 BST			5-day change	1st Jan Change
253 ^CHF	-0.14%		+2.18%	+3.60%

06-25	Halozyme Therapeutics Says Roche's OCREVUS SC With ENHANZE Gets European Commission Approval	MT
06-25	Roche: approval of Ocrevus SC in Europe	CF

ROCHE HOLDINGS AG : JP Morgan gives a Sell rating

June 17, 2024 at 06:54 am

JP Morgan analyst Richard Vosser reiterate his Sell rating on the stock. The target price is still set at CHF 210.

Latest news about Roche Holding AG

Halozyme Therapeutics Says Roche's OCREVUS SC With ENHANZE Gets European Commission Approval	06-25	MT
Roche: approval of Ocrevus SC in Europe	06-25	CF
Roche Wins EU Nod for Subcutaneous Formula of Multiple Sclerosis Drug Ocrevus	06-25	MT
Roche's Multiple Sclerosis Injection Gets EU Approval	06-25	DJ
Halozyme Therapeutics, Inc. Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis	06-25	CI
Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis	06-25	CI
Swiss Market Index in Green as Investors Keep Eye on European Politics	06-24	MT
Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm...	06-24
Foreign banks target Switzerland after UBS takeover of Credit Suisse	06-24	RE
ROCHE HOLDINGS AG : Barclays reiterates its Neutral rating	06-24	ZD
Roche: two new units for cobas pro	06-24	CF
Roche: marketing authorization application validated for Elevidys in Europe	06-24	CF
European Medicines Agency Begins Review of Roche's Gene Therapy for Duchenne Muscular Dystrophy	06-24	MT
US FDA approves Roche's drug for a chronic blood disorder	06-21	RE
Nykredit Bank Initiates Coverage on Roche With Buy Recommendation	06-21	MT
Nykredit Bank Starts Roche Coverage at Buy	06-21	MT
Sarepta Therapeutics Gets Expanded Label FDA Approval for Duchenne Muscular Dystrophy; Shares Soar Premarket	06-21	MT
Sarepta Therapeutics Gets Expanded US FDA Approval for Treatment of Duchenne Muscular Dystrophy; Shares Soar After Hours	06-20	MT
US FDA approves expanded use of Sarepta's Duchenne gene therapy; shares jump	06-20	RE
Sarepta Shares Soar 37% Following Expanded Approval for Elevidys	06-20	DJ
Sarepta Therapeutics, Inc. Announces Expanded US FDA Approval of Eletidys to Duchenne Muscular Dystrophy Patients Ages 4 and Above	06-20	CI
ROCHE HOLDINGS AG : UBS reiterates its Neutral rating	06-20	ZD
Swiss Equities Close Higher as SNB Delivers Another Rate Cut	06-20	MT
Roche: new detection test for lymphoma	06-20	CF
Roche Launches First Clinically Approved Test for B-cell Lymphoma	06-20	MT

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

23/07/2024 - American Society of Retina Specialists Meeting

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 04:50 pm

Obesity: Roche joins the battle

December 04, 2023 at 03:48 pm

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

253.4 CHF

Average target price

278.1 CHF

Spread / Average Target

+9.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	+3.60%	229B
ELI LILLY AND COMPANY	+55.19%	815B
NOVO NORDISK A/S	+45.71%	654B
JOHNSON & JOHNSON	-6.09%	354B
MERCK & CO., INC.	+21.92%	337B
ASTRAZENECA PLC	+19.68%	247B
NOVARTIS AG	+14.05%	219B
AMGEN INC.	+10.86%	171B
PFIZER, INC.	-2.78%	159B
SANOFI	+1.79%	122B

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : JP Morgan gives a Sell rating

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals